UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder

Ergisi, Mehmet; Erridge, Simon; Harris, Michael; Kawka, Michal; Nimalan, Devaki; Salazar, Oliver; Loupasaki, Katerina; Ali, Rayyan Al; Holvey, Carl; Coomber, Ross; Platt, Michael; Rucker, James; Sodergren, Mikael H.

doi:10.1080/17512433.2022.2020640

Cited by 27 publications

(32 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The implications of stigma towards CBMPs are potentially barriers to seeking treatment in the UK. As previously noted, this is disappointing considering the unmet clinical need of refractory chronic illness, such as pain and anxiety, which may otherwise benefit from a trial of CBMPs [ 11 , 15 ]. Compared with previous research [ 4 , 5 , 12 , 13 ] this study shows that patients report feeling uncomfortable in seeking treatment despite its legal status.…”

Section: Discussionmentioning

confidence: 99%

“…The present study is also limited to respondents from one clinic in the UK. However, Sapphire Medical Clinics were the first clinic registered with appropriate regulators and have set up the UK Medical Cannabis Registry, which is the largest prospective observational cohort dataset of clinical outcomes following CBPM therapy of its kind in Europe [ 9 , 10 , 11 ]. Moreover, they treat patients across all four nations in the UK and Channel Islands, ensuring geographic diversity.…”

Section: Discussionmentioning

confidence: 99%

“…It can also lead to chronic stress and anxiety, in addition to subsequent mental and physical problems that can cause individuals to feel isolated and withdrawn [ 5 , 7 ], therefore limiting access [ 8 ]. Whilst there is a growing body of evidence on the associated effects of CBMPs on health-related quality of life in several health conditions [ 9 , 10 , 11 ], there is a paucity of knowledge on the prevalence and subsequent effects of stigma on the current and prospective UK patients [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

Troup

Erridge

Ciesluk

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

Cannabis-based medicinal products (CBMPs) are prescribed with increasing frequency. This study aimed to investigate the perceived stigma attached to patients prescribed CBMPs in the UK to establish its prevalence. A qualitative survey was developed by an expert multidisciplinary group and data were collected via Qualtrics. In total, 2319 patients on CBMP therapy were invited to take part in this study. 450 (19.4%) participants completed the questionnaire. In total, 81.3% (n = 366), 76.9% (n = 346), and 61.3% (n = 276) of participants reported feeling very comfortable or comfortable telling friends, family, and medical professionals, respectively, about their treatment. Participants thought that friends (n = 372; 82.7%) and family (n = 339; 75.3%) were very approving or somewhat approving of their CBMP prescription. However, participants thought that only 37.8% (n = 170) of healthcare professionals and 32.9% (n = 148) of society in general were very approving or somewhat approving of their CBMP prescription. 57.1% (n = 257), 55.3% (n = 249), and 40.2% (n = 181) of participants were afraid of what the police or criminal justice system, other government agencies, and healthcare professionals might think about their treatment. This study highlights those patients treated with CBMPs experience a high prevalence of perceived stigma from many corners of society. Future work should be undertaken to explore strategies to reduce perceived stigma at an individual and community level to avoid discrimination of patients, likely increasing appropriate access.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

Troup

Erridge

Ciesluk

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous smaller studies have demonstrated improvements in patient reported outcomes over shorter periods of time and with mixed cannabis delivery systems including inhaled and oromucosal medications [7, 22], and for specific clinical conditions in pain [23, 24], anxiety [25,26], cancer [27,28], and sleep [29]. This is the first comprehensive analysis of this magnitude and length of time for oral MC daily dosages prescribed in a cannabis naïve cohort.…”

Section: Discussionmentioning

confidence: 99%

“…These studies have nearly all included smaller numbers of patients (fewer than 200) and have reported on shorter outcomes at 6 or 12 month follow up periods. In addition, they have little or no information on doses or ratios of THC and CBD [6,7,8,9]. A recent study by Schneider et al 2022 of registry data of 10,000 patients from Israel’s largest clinic, observed high safety, decrease in pain levels and improvements in QOL on 4166 patients that reported at 6-month follow-up, however this study included a range of MC formulations -smoking, vaporised or sublingual oil [10].…”

Section: Introductionmentioning

confidence: 99%

A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years

Vickery

Roth²,

Ernenwein³

et al. 2022

Preprint

View full text Add to dashboard Cite

Title : A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. Introduction : Oral medicinal cannabis (MC) has been increasingly prescribed for a wide range of clinical conditions since 2016. Despite an exponential rise in prescriptions and publications, high quality clinical efficacy and safety studies are lacking. The outcomes of a large Australian clinical electronic registry cohort are presented. Methods : A prospective cannabis-naïve patient cohort prescribed oral MC participated in an ongoing longitudinal registry at a network of specialised clinics. Patient MC dose, safety and validated outcome data were collected regularly over two years and analysed. Results : 3,961 patients (mean age 56.07 years [SD 19.08], 51.0% female) with multimorbidity (mean diagnoses 5.14 [SD 4.08]). and polypharmacy (mean 6.26 medications [SD 4.61]). Clinical indications were for; chronic pain (71.9%) psychiatric (15.4%), neurological (2.1%), and other diagnoses (10.7%). Median total oral daily dose was 10mg for Δ9-tetrahydrocannabinol (THC) and 22.5mg for cannabidiol (CBD). A stable dose was observed for over two years. Treatment related adverse events (37.3%) were mild (dry mouth 79.9%), dose-related (sedation/dizziness, 68.2%) with fewer than 2% (n=23) experiencing severe and only two serious adverse events. Highly significant improvements across all outcomes were sustained for over two years, including: clinical global impression (CGI-E, +39%: CGI-I, +52%; p<0.001), pain interference and severity (BPI, 26.1% and 22.2%; p<0.001), mental health (DASS-21, depression 24.5%, anxiety 25.5%, stress 27.7%; p<0.001), insomnia (ISI, 35.0%; p<0.001), and health status (RAND SF36: Physical function, 34.4%: Emotional well-being, 37.3%; p<0.001). Mean number of concomitant medications did not significantly change over 2 years. Conclusions : Oral MC was demonstrated to be safe and well-tolerated for a sustained period in a large complex cohort of cannabis-naïve, multimorbid patients with polypharmacy. There was highly significant improvement across all clinical outcomes over two years. Results are subject to limitations of real world data for causation and generalisability. Future high quality randomised controlled trials are awaited.

show abstract

UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia

Vivek,

Karagozlu,

Erridge

et al. 2024

Brain and Behavior

Self Cite

View full text Add to dashboard Cite

IntroductionThe primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia.MethodsA case series of UK patients with insomnia was analyzed. Primary outcomes were changes in the Single‐Item Sleep‐Quality Scale (SQS), Generalized Anxiety Disorder‐7 (GAD‐7), and EQ‐5D‐5L at up to 6 months from baseline. Statistical significance was identified as a p value < .050.Results61 patients were included in the analysis. There was an improvement in the SQS from baseline at 1, 3, and 6 months (p < .001). There were also improvements in the EQ‐5D‐5L Index value and GAD‐7 at 1, 3, and 6 months (p < .050). There were 28 (45.9%) adverse events recorded by 8 patients (13.1%). There were no life‐threatening/disabling adverse events.ConclusionPatients with insomnia experienced an improvement in sleep quality following the initiation of CBMPs in this medium‐term analysis. Fewer than 15% of participants reported one or more adverse events. However, due to the limitations of the study design, further investigation is required before definitive conclusions can be drawn on the efficacy of CBMPs in treating insomnia.

show abstract

UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder

Cited by 27 publications

References 55 publications

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

Perceived Stigma of Patients Undergoing Treatment with Cannabis-Based Medicinal Products

A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years

UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia

Contact Info

Product

Resources

About